Kjellin M.; Wesslén T.; Löfblad E.; Lennerstrand J.; Lannergård A. The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort. Upsala Journal of Medical Sciences, v. 123, n. 1, p. 50–56, 14 Mar. 2018.